Table 3.

Association of rs9623117 at 22q13 with prostate cancer risk

StudyRisk alleleGenotyped counts (TT, TC, CC)Allele frequencyP*P#Allelic OR (95% CI)
CasesControlsCasesControls
A. Aggressive disease
    CAPSC745411671,080535630.220.200.021.17 (1.03-1.33)
    JHHC52336549287161140.250.200.011.28 (1.05-1.55)
    ATBCC1458112638246360.220.170.021.35 (1.06-1.74)
    FPCCC36924443409207390.250.220.041.21 (1.01-1.45)
    HPFSC68428360224260.250.230.511.11 (0.81-1.54)
    PLCOC38426043684385310.250.206.60E−041.32 (1.12-1.55)
    ACSC527337491,034648930.240.230.791.02 (0.89-1.16)
    ALLC2,7511,7352694,4922,4063020.240.214.96E−070.191.18 (1.11-1.26)
B. Nonaggressive disease
    CAPSC970570731,080535630.220.200.011.16 (1.03-1.31)
    JHHC28720322287161140.240.200.051.24 (1.00-1.53)
    ATBCC34514420638246360.180.170.591.06 (0.86-1.29)
    FPCCC00040920739NA0.22NANA
    HPFSC21714824360224260.250.230.191.15 (0.93-1.42)
    PLCOC29317421684385310.220.200.251.11 (0.93-1.34)
    ACSC393264251,034648930.230.230.730.97 (0.84-1.13)
    ALLC2,4861,4901864,4922,4063020.220.214.00E−30.431.11 (1.03-1.18)
  • NOTE: P*: based on allelic test assuming multiplicative model. The combined tests are based on M-H test.

  • P#: Breslow-Day test for homogeneity.